How to Anticipate and Avoid Trouble

36. Nesheim M, Wang W, Boffa M, agashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAF! in the molecular link between coaglllation and fibrinolysis. Thromb Haemost 1997;78:386-91. 37. lhang l, lhang L, Yepes M, Jiang Q, Li Q, Amiego p et al. Adjllvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolie stroke. Circulation 2002;106:740-5. 38. Yepes M, Sandkvist M, Wong MK, Coleman TA, Smith E, Cohan SL et al. Neuroserpin redlIces cerebrai infarct volume and protects neurons from ischemia-induced apoptosis. Blood 2000;96:569-76. 39. Cinelli P, Madani R, Tsuzuki N, Vallet P, Arras M, Zhao CN et al. Nellroserpin, a nellroprotective factor in focal ischemic stroke. Mol Celi Neurosci 2001;18: 443-57 40. Zhang L, lhang ZG, lhang RL, Lu M, AdamsJ, Elliott PJ et al. Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolie focal cerebral ischemia. Stroke 2001;32:2926-31. 41. Lapchak PA, Chapman DF, livinJA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolie stroke. Stroke 2000;31 :3034-40.

2. Cite available methods to treat complications associated with complex venous access. Panelists: Sanford Altman, MD Richard J. Gray, MD Ziv Haskal, MD Jeet Sandhu, MD Karim Valji, MD

Lessons Learned: Aortic Stent Grafts

Saturday, March 29, 2003 5:00 p.m.-6:30 p.m. Coordinator/Moderator: Richard A. Baum, MD Objectives: l. Explore pitfalls and problems when performing endovascular AAA repair.

2. Leam how to avoid and get out of trouble when performing endovascular AAA repair. 5:00 p.m. The MGH Experience Chieh-Min Fan, MD Massachusetts General HQspital Boston, MA

42. Reglodi D, Somogyvari-Vigh A, Vigh S, Kozicz T, Arimura A. Delayed systemie administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke 2000;31: 1411-7.

5:30 p.m. How to Anticipate and Avoid Trouble Ricbard A. Baum, MD Brigham and Women's Hospital Boston, MA

43. Lapchak PA, Araujo DM, Song D, Wei J, Zivin JA. Neuroprotective effects of the spin trap agent disodium-[(telt-buty li mino)methyl] benzene-1 ,3-disulfonate N-oxide (generic NXY-059) in a rabbit smali ciot embolie stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 2002;33:1411-5.

6:00 p.m. Q&A

4:25 p.m. Q&A

Saturday, March 29, 2003 5:00 p.m.-6:30 p.m.

Non-Invasive Vascular lab I

Coordinator/Moderator: Keith M. Sterling, MD

Lessons learned: Complex Venous Access

Saturday, March 29, 2003 3:00 p.m.-4:30 p.m. Coordinator/Moderator: Richard J. Gray, MD Objectives: l. Describe the complications associated with complex venous access.

Objectives: l. Discuss the importance of the noninvasive vascular la boratory in the diagnosis of patients with peripheral vascular disease.

2. Discuss the factors needed to start and run a successful noninvasive vascular laboratory. 3. Name the unique ways in which interventional radiologists can use the noninvasive vascular laboratolY to expand their clinical practices. 4. Evaluate the different state-of-the-art noninvasive moP249